ONLINE NEWS AND PRINT MEDIA
Have a look at various news about us in media
RPG Life Sciences is prioritizing its API business for future growth, planning a significant acquisition to scale operations. The company also aims to enter the GLP-1 weight-loss therapy market by August-September. Despite geopolitical risks, RPG Life Sciences is strategically focusing on niche, complex molecules and expanding into new therapy areas.
Ashok Nair, managing director, RPG Life Sciences, said:
"Overall, we have built solid momentum with healthy growth in Q4 and for the full fiscal year, driven by sharper field effectiveness, operational discipline and an unwavering focus on our key brands.
Looking ahead, we intend to strengthen our new product pipeline, sharpen equity of our existing brands, and drive field force effectiveness."
Ashok Nair, MD of RPG Life Sciences said the company delivered strong revenue and profit growth, with expansion across therapy areas and stable margins expected going forward, supported by pricing actions and business expansion.
The board of RPG Life Sciences Technologies has recommended a dividend of ₹24 per equity share, or 300 per cent on the face value of ₹8 per share, fully paid up, for FY26
Bajaj Finance share price rose 4 percent after reporting a strong operational performance, with its Q4 consolidated profit rising 22 percent year-on-year to Rs 5,553 crore.
Shares of RPG Life Sciences Ltd ended at ₹2,024.05, down by ₹34.70, or 1.69%, on the BSE.
RPG LIFE SCIENCES share price has zoomed 10% and is presently trading at Rs 2,228.4.
Ashok Nair MD, RPG Life Sciences speaks to ZEE Business on the company's Q4 FY26 performance